Diabetes drug may protect against deadly form of breast cancer

New research identified a metabolic enzyme inhibitor used to treat diabetes could be used to treat "basal-like" types breast cancer.
By Amy Wallace   |   March 7, 2017 at 3:12 PM

March 7 (UPI) -- Researchers in China have discovered a metabolic enzyme inhibitor called epalrestat, used to treat complications from diabetes, could be effective in fighting a deadly form of breast cancer.

The metabolic enzyme AKR1B1 promotes the growth of the deadly form of basal-like and triple-negative breast cancer.

Between 15 and 20 percent of all breast cancers are basal-like, which is particularly aggressive and falls into the triple-negative breast cancer subtype. Currently, there are no effective treatments for this form of breast cancer, which is often fatal.

Basal-like breast cancer is more aggressive due to a process called epithelial-mesenchymal transition, or EMT, a process where cancer cells become more capable of motion and gain stem cell-like properties allowing them to resist treatment and metastasize.

Researchers discovered levels of AKR1B1 were significantly higher in basal-like and triple-negative breast cancers, which was linked to increased rates of metastasis and death.

Conversely, researchers found that knocking down AKR1B1 inhibited the growth and metastasis of tumors in basal-like breast cancer cells injected into mice.

The study also revealed epalrestat, a drug used to treat peripheral diabetic neuropathies, inhibits AKR1B1 and can block the growth and metastasis of basal-like breast cancer cells.

"Our data clearly suggests that AKR1B1 overexpression represents an oncogenic event that is responsible for the aggressive behaviors of basal-like breast cancer cells," Chenfang Dong, a researcher at the Zhejiang University School of Medicine in Hangzhou, China, said in a press release. "Since epalrestat is already on the market and has no major adverse side effects, our study provides a proof of principle that it could become a valuable targeted drug for the clinical treatment of basal-like breast cancer."

The study was published in The Journal of Experimental Medicine.

Follow us on Facebook, Twitter, and Instagram for more news from UPI.com
Related UPI Stories
share with facebook
share with twitter
Trending Stories